1. Gabow P.A.. Autosomal dominant polycystic kidney disease.
N Engl J Med 329:1993;332–342.
2. Nauli S.M., Alenghat F.J., Luo Y., Williams E., Vassilev P., Li X., Elia A.E., Lu W., Brown E.M., Quinn S.J., Ingber D.E., Zhou J.. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells.
Nat Genet 33:2003;129–137.
3. Belibi F., Edelstein C.L.. Novel targets for the treatment of autosomal dominant polycystic kidney disease.
Expert Opin Investig Drugs 19:2010;315–328.
4. Chang M., Ong A.C.. Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects.
Nephron Clin Pract 120:2012;c25–c35.
5. Wilson P.D.. Polycystic kidney disease.
N Engl J Med 350:2004;151–164.
6. Trudel M., D'Agati V., Costantini F.. C-myc as an inducer of polycystic kidney disease in transgenic mice.
Kidney Int 39:1991;665–671.
7. Schaffner D.L., Barrios R., Massey C., Bañez E.I., Ou C.N., Rajagopalan S., Aguilar-Cordova E., Lebovitz R.M., Overbeek P.A., Lieberman M.W.. Targeting of the rasT24 oncogene to the proximal convoluted tubules in transgenic mice results in hyperplasia and polycystic kidneys.
Am J Pathol 142:1993;1051–1060.
8. Fingar D.C., Blenis J.. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.
Oncogene 23:2004;3151–3171.
9. Torres V.E., Boletta A., Chapman A., Gattone V., Pei Y., Qian Q., Wallace D.P., Weimbs T., Wüthrich R.P.. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.
Clin J Am Soc Nephrol 5:2010;1312–1329.
10. Gao X., Zhang Y., Arrazola P., Hino O., Kobayashi T., Yeung R.S., Ru B., Pan D.. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling.
Nat Cell Biol 4:2002;699–704.
11. Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S., Tokunaga C., Avruch J., Yonezawa K.. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action.
Cell 110:2002;177–189.
12. Burnett P.E., Barrow R.K., Cohen N.A., Snyder S.H., Sabatini D.M.. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1.
Proc Natl Acad Sci USA 95:1998;1432–1437.
13. Oshiro N., Yoshino K., Hidayat S., Tokunaga C., Hara K., Eguchi S., Avruch J., Yonezawa K.. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function.
Genes Cells 9:2004;359–366.
14. Huang J., Manning B.D.. A complex interplay between Akt, TSC2 and the two mTOR complexes.
Biochem Soc Trans 37:2009;217–222.
15. Wullschleger S., Loewith R., Hall M.N.. TOR signaling in growth and metabolism.
Cell 124:2006;471–484.
16. Foster K.G., Fingar D.C.. Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony.
J Biol Chem 285:2010;14071–14077.
17. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M.. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.
Science 307:2005;1098–1101.
18. Sparks C.A., Guertin D.A.. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy.
Oncogene 29:2010;3733–3744.
19. Hoang B., Frost P., Shi Y., Belanger E., Benavides A., Pezeshkpour G., Cappia S., Guglielmelli T., Gera J., Lichtenstein A.. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.
Blood 116:2010;4560–4568.
20. Martiny-Baron G., Fabbro D.. Classical PKC isoforms in cancer.
Pharmacol Res 55:2007;477–486.
21. Boehlke C., Kotsis F., Patel V., Braeg S., Voelker H., Bredt S., Beyer T., Janusch H., Hamann C., Gödel M., Müller K., Herbst M., Hornung M., Doerken M., Köttgen M., Nitschke R., Igarashi P., Walz G., Kuehn E.W.. Primary cilia regulate mTORC1 activity and cell size through Lkb1.
Nat Cell Biol 12:2010;1115–1122.
22. Bell P.D., Fitzgibbon W., Sas K., Stenbit A.E., Amria M., Houston A., Reichert R., Gilley S., Siegal G.P., Bissler J., Bilgen M., Chou P.C., Guay-Woodford L., Yoder B., Haycraft C.J., Siroky B.. Loss of primary cilia upregulates renal hypertrophic signaling and promotes cystogenesis.
J Am Soc Nephrol 22:2011;839–848.
23. Becker J.U., Saez A.O., Zerres K., Witzke O., Hoyer P.F., Schmid K.W., Kribben A., Bergmann C., Nurnberger J.. The mTOR pathway is activated in human autosomal-recessive polycystic kidney disease.
Kidney Blood Press Res 33:2010;129–138.
24. Fischer D.C., Jacoby U., Pape L., Ward C.J., Kuwertz-Broeking E., Renken C., Nizze H., Querfeld U., Rudolph B., Mueller-Wiefel D.E., Bergmann C., Haffner D.. Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD).
Nephrol Dial Transplant 24:2009;1819–1827.
25. Tao Y., Kim J., Schrier R.W., Edelstein C.L.. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease (PKD).
J Am Soc Nephrol 16:2005;46–51.
26. Wahl P.R., Serra A.L., Le Hir M., Molle K.D., Hall M.N., Wüthrich R.P.. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
Nephrol Dial Transplant 21:2006;598–604.
27. Wu M., Wahl P.R., Le Hir M., Wackerle-Men Y., Wuthrich R.P., Serra A.L.. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease.
Kidney Blood Press Res 30:2007;253–259.
28. Shillingford J.M., Murcia N.S., Larson C.H., Low S.H., Hedgepeth R., Brown N., Flask C.A., Novick A.C., Goldfarb D.A., Kramer-Zucker A., Walz G., Piontek K.B., Germino G.G., Weimbs T.. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease.
Proc Natl Acad Sci USA 103:2006;5466–5471.
29. Zafar I., Belibi F.A., He Z., Edelstein C.L.. Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD).
Nephrol Dial Transplant 24:2009;2349–2353.
30. Belibi F., Ravichandran K., Zafar I., He Z., Edelstein C.L.. mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease.
Am J Physiol Renal Physiol 300:2011;F236–F244.
31. Shillingford J.M., Piontek K.B., Germino G.G., Weimbs T.. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.
J Am Soc Nephrol 21:2010;489–497.
32. Zafar I., Ravichandran K., Belibi F., Doctor R.B., Edelstein C.L.. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.
Kidney Int 78:2010;754–761.
33. Wu M., Arcaro A., Varga Z., Vogetseder A., Le Hir M., Wuthrich R.P., Serra A.L.. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease.
Am J Physiol Renal Physiol 297:2012;F1597–F1605.
34. Renken C., Fischer D.C., Kundt G., Gretz N., Haffner D.. Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats.
Nephrol Dial Transplant 26:2011;92–100.
35. Novalic Z., van der Wal A.M., Leonhard W.N., Keohl G., Breuning M.H., Geissler E.K., de Heer E., Peters D.J.. Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease.
J Am Soc Nephrol 23:2012;842–853.
36. Takiar V., Nishio S., Seo-Mayer P., King J.D. Jr., Li H., Zhang L., Karihaloo A., Hallows K.R., Somlo S., Caplan M.J.. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis.
Proc Natl Acad Sci USA 106:2011;2462–2467.
37. Anderson S., Oyama T.T., Lindsley J.N., Schutzer W.E., Beard D.R., Gattone V.H., Komers R.. 2-Hydroxyestradiol slows progression of experimental polycystic kidney disease.
Am J Physiol Renal Physiol 302:2012;F636–F645.
38. Qin S., Taglienti M., Nauli S.M., Contrino L., Takakura A., Zhou J., Kreidberg J.A.. Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease.
J Clin Invest 120:2010;3617–3628.
39. Qian Q., Hui D., King B.F., Kumar S., Dean P.G., Cosio F.G., Torres V.E.. Sirolimus reduces polycystic liver volume in ADPKD patients.
J Am Soc Nephrol 19:2008;631–638.
40. Perico N., Antiga L., Caroli A., Ruggenenti P., Fasolini G., Cafaro M., Ondei P., Rubis N., Diadei O., Gherardi G., Prandini S., Panozo A., Bravo R.F., Carminati S., De Leon F.R., Gaspari F., Cortinovis M., Motterlini N., Ene-Iordache B., Remuzzi A., Remuzzi G.. Sirolimus therapy to halt the progression of ADPKD.
J Am Soc Nephrol 21:2010;1031–1040.
41. Walz G., Budde K., Mannaa M., Nurnberger J., Wanner C., Sommerer C., Kunzendorf U., Banas B., Hörl W.H., Obermüller N., Arns W., Pavenstädt H., Gaedeke J., Büchert M., May C., Gschaidmeier H., Kramer S., Eckardt K.U.. Everolimus in patients with autosomal dominant polycystic kidney disease.
New Engl J Med 363:2010;830–840.
42. Serra A.L., Poster D., Kistler A.D., Krauer F., Raina S., Young J., Rentsch K.M., Spanaus K.S., Senn O., Kristanto P., Scheffel H., Weishaupt D., Wüthrich R.P.. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
New Engl J Med 363:2010;820–829.
43. Watnick T., Germino G.G.. mTOR inhibitors in polycystic kidney disease.
New Engl J Med 363:2010;879–881.
44. Perico N., Remuzzi G.. Do mTOR inhibitors still have a future in ADPKD?
Nar Rev Nephrol 6:2010;696–698.
45. Canaud G., Knebelmann B., Harris P.C., Vrtovsnik F., Correas J.M.. Pallet N, Heyer CM, Letavernier E, Bienaimé F, Thervet E, Martinez F, Terzi F, Legendre C: Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?
Am J Transplant 10:2010;1701–1706.
46. Ponticelli C., Locatelli F.. Autosomal dominant polycystic kidney disease and mTOR inhibitors:the narrow road between hope and disappointment.
Nephrol Dial Transplant 25:2010;3809–3812.
47. Shor B., Gibbons J.J., Abraham R.T., Yu K.. Targeting mTOR globally in cancer; thinking beyond rapamycin.
Cell Cycle 8:2009;3831–3837.